[go: up one dir, main page]

WO2017175184A1 - Procédé de préparation de la forme amorphe d'idélalisib - Google Patents

Procédé de préparation de la forme amorphe d'idélalisib Download PDF

Info

Publication number
WO2017175184A1
WO2017175184A1 PCT/IB2017/052002 IB2017052002W WO2017175184A1 WO 2017175184 A1 WO2017175184 A1 WO 2017175184A1 IB 2017052002 W IB2017052002 W IB 2017052002W WO 2017175184 A1 WO2017175184 A1 WO 2017175184A1
Authority
WO
WIPO (PCT)
Prior art keywords
idelalisib
amorphous form
temperature
solution
carried out
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2017/052002
Other languages
English (en)
Inventor
Nagaraju MEKALA
Srinivasa Rao BUDDEPU
Rajesh EDUPUGANTI
Sanjay Kumar Dehury
Ram Thaimattam
Venkata Sunil Kumar Indukuri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laurus Labs Pvt Ltd
Original Assignee
Laurus Labs Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laurus Labs Pvt Ltd filed Critical Laurus Labs Pvt Ltd
Publication of WO2017175184A1 publication Critical patent/WO2017175184A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Definitions

  • the step of providing a solution of Idelalisib may include dissolving any form of Idelalisib, in one or more organic solvents.
  • the organic solvents include, but are not limited to diols, ketones, sulfoxides, esters, nitriles and the like and mixtures thereof.
  • the step of providing a solution of Idelalisib may include dissolving any form of Idelalisib in acetone.
  • the contents may be heated to a suitable temperature.
  • the solution is heated at a temperature of at least about 30°C to about reflux; preferably at about 45°C to about 65°C.
  • the Idelalisib in the step a) may be any crystalline or other form of Idelalisib, including various solvates, hydrates, salts and cocrystals as long as amorphous Idelalisib is produced during the process of the invention or Idelalisib obtaining as existing solution from a previous processing step.
  • the step of providing a solution of Idelalisib may include dissolving any form of Idelalisib in 1-propanol at a temperature of about 25°C to about reflux temperature; preferably at about 35°C to about 75°C.
  • the crystalline Idelalisib obtained by the above process may be dried in, for example, a Vacuum Tray Dryer, Rotocon Vacuum Dryer, Vacuum Paddle Dryer or pilot plant Rota vapor at a temperature of about 45°C to 85°C to obtain amorphous form of Idelalisib.
  • the present invention provides crystalline Idelalisib, characterized by a powder X-Ray diffraction (PXRD) pattern substantially in accordance with Figure 5.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne de manière générale des procédés de préparation de la forme amorphe d'Idélalisib et une composition pharmaceutique comprenant cette dernière.
PCT/IB2017/052002 2016-04-07 2017-04-07 Procédé de préparation de la forme amorphe d'idélalisib Ceased WO2017175184A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201641012262 2016-04-07
IN201641012262 2016-04-07

Publications (1)

Publication Number Publication Date
WO2017175184A1 true WO2017175184A1 (fr) 2017-10-12

Family

ID=60000968

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2017/052002 Ceased WO2017175184A1 (fr) 2016-04-07 2017-04-07 Procédé de préparation de la forme amorphe d'idélalisib

Country Status (1)

Country Link
WO (1) WO2017175184A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10370376B2 (en) * 2015-04-15 2019-08-06 Alnova Pharmaceuticals, Ltd. Amorphous substance of Idelalisib and preparation method therefor
WO2019178596A1 (fr) 2018-03-16 2019-09-19 Johnson Matthey Public Limited Company Formes à l'état solide solvatées de pyridine ou de n,n-diméthylacétamide d'idélalisib solvaté, leur utilisation et leur préparation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013134288A1 (fr) * 2012-03-05 2013-09-12 Gilead Calistoga Llc Formes polymorphes de l'acide -2-(1-(9h-purine-6-ylamino)propyl)-5-fluoro-3-phénylquinazolin-4(3h)-one
WO2015014315A1 (fr) * 2013-08-01 2015-02-05 杭州普晒医药科技有限公司 Forme cristalline d'inhibiteur et son procédé de préparation et son utilisation
WO2015095605A1 (fr) * 2013-12-20 2015-06-25 Gilead Calistoga Llc Formes polymorphes d'un sel chlorhydrate de la (s)-2-(9h-purine-6-ylamino)propyl)-5-fluoro-3-phénylquinazolin-4(3h)-one
WO2015092810A2 (fr) * 2013-11-20 2015-06-25 Cadila Healthcare Limited Forme amorphe d'idélalisib

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013134288A1 (fr) * 2012-03-05 2013-09-12 Gilead Calistoga Llc Formes polymorphes de l'acide -2-(1-(9h-purine-6-ylamino)propyl)-5-fluoro-3-phénylquinazolin-4(3h)-one
WO2015014315A1 (fr) * 2013-08-01 2015-02-05 杭州普晒医药科技有限公司 Forme cristalline d'inhibiteur et son procédé de préparation et son utilisation
WO2015092810A2 (fr) * 2013-11-20 2015-06-25 Cadila Healthcare Limited Forme amorphe d'idélalisib
WO2015095605A1 (fr) * 2013-12-20 2015-06-25 Gilead Calistoga Llc Formes polymorphes d'un sel chlorhydrate de la (s)-2-(9h-purine-6-ylamino)propyl)-5-fluoro-3-phénylquinazolin-4(3h)-one

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10370376B2 (en) * 2015-04-15 2019-08-06 Alnova Pharmaceuticals, Ltd. Amorphous substance of Idelalisib and preparation method therefor
WO2019178596A1 (fr) 2018-03-16 2019-09-19 Johnson Matthey Public Limited Company Formes à l'état solide solvatées de pyridine ou de n,n-diméthylacétamide d'idélalisib solvaté, leur utilisation et leur préparation
US11358966B2 (en) 2018-03-16 2022-06-14 Johnson Matthey Public Limited Company Pyridine or N,N-dimethyl acetamide solvated solid state forms of solvated idelalisib, their use and preparation

Similar Documents

Publication Publication Date Title
US10738038B2 (en) Co-crystals of SGLT2 inhibitors, process for their preparation and pharmaceutical compositions thereof
US11760757B2 (en) Solid state forms of lumateperone ditosylate salt
US10035802B2 (en) Solid state forms of ibrutinib
EP3337485B1 (fr) Formes cristallines d'ibrutinib
EP3218351B1 (fr) Procédé de préparation, d'isolation et de purification de formes pharmaceutiquement applicables de ahu-377
US20090076272A1 (en) Polymorphs of eszopiclone malate
JP2021105003A (ja) 多形体及びキナゾリニル誘導体の調製プロセス
US20210300950A1 (en) Solid state forms of ixazomib citrate
US20080167477A1 (en) Novel polymorphic forms of carvedilol dihydrogen phosphate and process for preparing the same
WO2019186522A1 (fr) Procédé amélioré de préparation du lopinavir et de ses intermédiaires
WO2017175184A1 (fr) Procédé de préparation de la forme amorphe d'idélalisib
WO2011080651A2 (fr) Formes polymorphes de fébuxostat
WO2011153221A1 (fr) Formes d'ixabepilone à l'état solide
WO2020234817A1 (fr) Formes polymorphes d'apalutamide et leur préparation
WO2014128728A2 (fr) Formes solides de cabazitaxel et leurs procédés de préparation
US20220009929A1 (en) Polymorphic forms of ibrutinib
CZ2003956A3 (cs) Způsob purifikace pravastatinu nebo jeho farmaceuticky přijatelné soli
US8993786B2 (en) Crystalline fosamprenavir calcium and process for the preparation thereof
WO2023141082A1 (fr) Formes à l'état solide de tipifarnib et leur procédé de préparation
WO2024033632A1 (fr) Procédé amélioré de préparation d'analogues de phosphonate antiviraux
US20110281928A1 (en) Process for the preparation of zofenopril and its pharmaceutically acceptable salts thereof
EA030947B1 (ru) Способ крупномасштабного производства 1-изопропил-3-{5-[1-(3-метоксипропил)пиперидин-4-ил]-[1,3,4]оксадиазол-2-ил}-1h-индазола оксалата
CN106957311B (zh) 雷替曲塞的溶剂化物及其制备方法
WO2019243799A1 (fr) Forme cristalline de sacubitril, sa préparation et son utilisation
WO2015166466A1 (fr) Forme cristalline d'acétate de saxagliptine

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17778773

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 17778773

Country of ref document: EP

Kind code of ref document: A1